Nanjing Sanhome Pharmaceutical, Co., Ltd.   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Nanjing China (1996)

Organization Overview

First Clinical Trial
2018
NCT03603262
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Nanjing Sanhome Pharmaceutical, Co., Ltd. | No.197 Ruijin Er Road, Shanghai, P.R China

Active Ingredients

Drugs in Phase 3 Trials (3)

daclatasvir (daklinza) (3 trials)

gefitinib (iressa) (1 trial)

Oritinib (8 trials)

Drugs in Phase 2 Trials (1)

shc014748m (4 trials)

Drugs in Phase 1 Trials (6)

itraconazole (sporanox) (1 trial)

rifampin (1 trial)

sh1573 (1 trial)

sh3051 (1 trial)

sh3765 (1 trial)

sh3809 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 3)

Communicable Diseases (Phase 1)

Hepatitis (Phase 3)

Hepatitis A (Phase 3)

Hepatitis C (Phase 3)

Hepatitis C, Chronic (Phase 3)

Infections (Phase 1)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Lung Neoplasms (Phase 3)

Lymphoma (Phase 2)

Lymphoma, B-Cell (Phase 1)

Lymphoma, B-Cell, Marginal Zone (Phase 2)

Lymphoma, Non-Hodgkin (Phase 1)

Lymphoma, T-Cell (Phase 2)

Lymphoma, T-Cell, Peripheral (Phase 2)

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 19
  • # of Trial APIs: 10